Your browser doesn't support javascript.
loading
Unravelling immune microenvironment features underlying tumor progression in the single-cell era.
Du, Qilian; An, Qi; Zhang, Jiajun; Liu, Chao; Hu, Qinyong.
Afiliação
  • Du Q; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • An Q; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Zhang J; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Liu C; Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, China. charles.liu@whu.edu.cn.
  • Hu Q; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. rm001223@whu.edu.cn.
Cancer Cell Int ; 24(1): 143, 2024 Apr 22.
Article em En | MEDLINE | ID: mdl-38649887
ABSTRACT
The relationship between the immune cell and tumor occurrence and progression remains unclear. Profiling alterations in the tumor immune microenvironment (TIME) at high resolution is crucial to identify factors influencing cancer progression and enhance the effectiveness of immunotherapy. However, traditional sequencing methods, including bulk RNA sequencing, exhibit varying degrees of masking the cellular heterogeneity and immunophenotypic changes observed in early and late-stage tumors. Single-cell RNA sequencing (scRNA-seq) has provided significant and precise TIME landscapes. Consequently, this review has highlighted TIME cellular and molecular changes in tumorigenesis and progression elucidated through recent scRNA-seq studies. Specifically, we have summarized the cellular heterogeneity of TIME at different stages, including early, late, and metastatic stages. Moreover, we have outlined the related variations that may promote tumor occurrence and metastasis in the single-cell era. The widespread applications of scRNA-seq in TIME will comprehensively redefine the understanding of tumor biology and furnish more effective immunotherapy strategies.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China